Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 19/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904475 | 0.93 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL29482251 | 0.84 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5600844 | 0.84 | CRHR1 (1.00) | CRHR1 | |
| Hydrochloric Acid SCHEMBL5872497 | 0.83 | CRHR1 (0.98) | CRHR1 | |
| Hydrochloric Acid SCHEMBL29601420 | 0.83 | CRHR1 (0.98) | CRHR1 | |
| SCHEMBL23460012 | 0.78 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL23486632 | 0.77 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL23460355 | 0.76 | CRHR1 (0.71) | CRHR1 | |
| SCHEMBL1235158 | 0.75 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL1236614 | 0.75 | CRHR1 (0.66) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | PFIZER INC. | 2001-11-15 | — | — | US | claimed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| US-6777404-B2 | SUCH AS 3-((4-METHYL-BENZYL)-(3,6-DIMETHYL-1-(2,4,6-TRIMETHYLPHENYL)-1H-PYRAZOLO -(3,4-D)PYRIMIDIN-4-YL)-AMINO)PROP AN-1-OL FOR TREATING/PREVENTING SYNDROME X; KITS | PFIZER INC | 2004-08-17 | — | — | US | disclosed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | disclosed |
| US-6589947-B1 | Treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist. | PFIZER INC. | 2003-07-08 | — | — | US | disclosed |
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | PFIZER INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041673-A1 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | CRH, GHSR, GHRHR | CRHR1 4/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.